Effect of the Anti-depressant Sertraline, the Novel Anti-seizure Drug Vinpocetine and Several Conventional Antiepileptic Drugs on the Epileptiform EEG Activity Induced by 4-Aminopyridine

Neurochemical Research

Volumn 41, Issue 6, 2016, Pages 1365-1374

  Sitges, Maria ^a   Aldana, Blanca Irene ^b   Reed, Ronald Charles ^c  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c HUSSON UNIVERSITY   (United States)

Author keywords

Carbamazepine; Lamotrigine; Levetiracetam; Oxcarbazepine; Phenytoin; Topiramate; Valproic acid

Indexed keywords

ANTICONVULSIVE AGENT; CALCIUM CHANNEL; CARBAMAZEPINE; FAMPRIDINE; LAMOTRIGINE; LEVETIRACETAM; OXCARBAZEPINE; PHENYTOIN; SERTRALINE; SODIUM CHANNEL; TOPIRAMATE; VALPROATE MAGNESIUM; VINPOCETINE; ANTIDEPRESSANT AGENT; VINCA ALKALOID;

ANIMAL MODEL; ARTICLE; BODY SURFACE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ELECTROENCEPHALOGRAM; HIGHEST PEAK AMPLITUDE VALUE; MALE; NERVOUS SYSTEM PARAMETERS; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE; ANIMAL; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; ELECTROENCEPHALOGRAPHY; PATHOPHYSIOLOGY; PROCEDURES; SEIZURES; TREATMENT OUTCOME; WISTAR RAT;

4-AMINOPYRIDINE; ANIMALS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; MALE; RATS; RATS, WISTAR; SEIZURES; SERTRALINE; TREATMENT OUTCOME; VINCA ALKALOIDS;

EID: 84969718887     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-016-1840-1     Document Type: Article

References (42)

1. + channel-mediated release of [3H]glutamate in hippocampal nerve endings. Neuropharmacology 52:598–605
2. + channel-mediated release. Neuropharmacology 53:854–862
3. Sitges M, Sanchez-Tafolla BM, Chiu LM, Aldana BI, Guarneros A (2011) Vinpocetine inhibits glutamate release induced by the convulsive agent 4-aminopyridine more potently than several antiepileptic drugs. Epilepsy Res 96:257–266
4. Yamaguchi S, Rogawski MA (1992) Effects of anticonvulsant drugs on 4-aminopyridine-induced seizures in mice. Epilepsy Res 11:9–16
5. Sitges M, Nekrassov V (2004) Vinpocetine prevents 4-aminopyridine-induced changes in the EEG, the auditory brainstem responses and hearing. Clin Neurophysiol 115:2711–2717
6. Mora G, Tapia R (2005) Effects of retigabine on the neurodegeneration and extracellular glutamate changes induced by 4-aminopyridine in rat hippocampus in vivo. Neurochem Res 30:1557–1565
7. Nekrassov V, Sitges M (2003) Effects of pentylenetetrazole and 4-aminopyridine on the auditory brainstem response (ABR) and on the hearing sensitivity in the guinea pig in vivo. Brain Res 53:245–254
8. Nekrassov V, Sitges M (2008) Comparison of acute, chronic and post-treatment effects of carbamazepine and vinpocetine on hearing loss and seizures induced by 4-aminopyridine. Clin Neurophysiol 119:2608–2614
9. Sitges M, Aldana BI, Gomez CD, Nekrassov V (2012) The antidepressant sertraline prevents the behavioral and EEG changes induced in two animal models of seizures. Epilepsy Behav 25:511–516
10. 2+ and glutamate release. J Neurochem 53:1693–1699
11. 2+ concentration and its relationship to B-50 (GAP-43) phosphorylation. J Neurochem 156:1827–1835
12. + induced by 4-aminopyridine (4-AP) in synaptosomes. Neurochem Res 29:347–355
13. Sitges M, Galvan E, Nekrassov V (2005) Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosomes. Neurochem Int 46:533–540
14. Gilliam F, Hecimovic H, Sheline Y (2003) Psychiatric comorbidity, health and function in epilepsy. Epilepsy Behav Suppl 4:S26–S30
15. Lothe A, Didelot A, Hammers A, Costes M, Saoud M, Gilliam F, Ryvlin P (2008) Comorbidity between temporal lobe epilepsy and depression: a [18F]MPPF PET study. Brain 131:2765–2782
16. Kanner AM (2008) Depression in epilepsy: a complex relation with unexpected consequences. Curr Opin Neurol 21:190–194
17. Kanner AM, Trimble M, Schmitz B (2010) Postictal affective episodes. Epilepsy Behav 19:156–158
18. Noe KH, Locke DE, Sirven JI (2011) Treatment of depression in patients with epilepsy. Curr Treat Options Neurol 13:371–379
19. Danzer SC (2011) Depression, stress, epilepsy and adult neurogenesis. Exp Neurol 233:22–32
20. Stevanovic D, Jancic J, Lakic A (2011) The impact of depression and anxiety disorder symptoms on the health-related quality of life of children and adolescents with epilepsy. Epilepsia 52:e75–e78
21. Hecimovic H, Santos JM, Carter J, Attarian HP, Fessier AJ, Vahle V, Gilliam F (2012) Depression but not seizure factors or quality of life predicts suicidality in epilepsy. Epilepsy Behav 24:426–429
22. Kanner AM, Schachter SC, Barry JJ, Hersdorffer DC, Mula M, Trimble M, Herman B, Ettinger AE, Dunn D, Caplan R, Ryvlin P, Gilliam F (2012) Depression and epilepsy: epidemiologic and Neurobiologic perspectives that may explain their high comorbid occurrence. Epilepsy Behav 24:156–168
23. Mula M (2012) Epilepsy: bidirectional link between epilepsy and psychiatric disorders. Nat Rev Neurol 8:252–253
24. Sheehan DV, Kamijima K (2009) An evidence-based review of the clinical use of sertraline in mood and anxiety disorders. Int Clin Psychopharmacol 24:43–60
25. + channel-mediated responses in hippocampus-isolated nerve endings. J Neurochem 121:197–205
26. Vohora D (2010) Recent advances in adjunctive therapy for epilepsy: focus on sodium channel blockers as third-generation antiepileptic drugs. Drugs Today 46:265–277
27. 2+]i rise in synaptosomes. NeuroReport 9:1849–1853
28. Sitges M, Nekrassov V (1999) Vinpocetine selectively inhibits neurotransmitter release triggered by sodium channel activation. Neurochem Res 24:1585–1591
29. 2+ and glutamate release in hippocampal isolated nerve endings. Neurochem Int 49:55–61
30. Nekrassov V, Sitges M (2004) Vinpocetine inhibits the epileptic cortical activity and auditory alterations induced by pentylenetetrazole in the guinea pig in vivo. Epilepsy Res 60:63–71
31. Tremaine LM, Welch WM, Ronfeld RA (1989) Metabolism and disposition of the 5-hydroxytryptamine uptake blocker sertraline in the rat and dog. Drug Metab Dispos 17:542–550
32. Sitges M, Garza-Morales S (2014) Effectiveness of a 12 h extended release formula of ethyl-apovincaminic acid in the control of seizures in patients with refractory epilepsy. Epilepsia 55(Suppl. 2):92–93
33. Reagan-Shaw S, Nihal M, Nihal A (2008) Dose translation from animal to human studies revisited. FASEB J 22:659–661
34. Gómez CD, Buijs RM, Sitges M (2014) The anti-seizure drugs vinpocetine and carbamazepine, but not valproic acid, reduce inflammatory IL-1β and TNF-α expression in rat hippocampus. J Neurochem 130:770–779
35. Schmidt D, Schachter S (2014) Drug treatment of epilepsy in adults. BMJ; 348-g2546
36. Bukanova J, Solntseva E, Skrebitsky V (2002) Selective suppression of the slow-inactivating potassium currents by nootropics in molluscan neurons. Int J Neuropsychopharmacol 5:229–237
37. Macdonald RL, Barker JL (1977) Pentylenetetrazol and penicillin are selective antagonists of GABA-mediated post-synaptic inhibition in cultured mammalian neurones. Nature 267:720–721
38. Löscher W (1999) Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action. Prog Neurobiol 58:31–59
39. Löscher W (2002) Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 16:669–694
40. Cramer CL, Stagnitto ML, Knowles MA, Palmer GC (1994) Kainic acid and 4-aminopyridine seizure models in mice: evaluation of efficacy of anti-epileptic agents and calcium antagonists. Life Sci 54:271–275
41. Martín ED, Pozo MA (2003) Valproate suppresses status epilepticus induced by 4-aminopyridine in CA1 hippocampus region. Epilepsia 44:1375–1379
42. Nekrassov V, Sitges M (2006) Additive effects of antiepileptic drugs and pentylenetetrazole on hearing. Neurosci Lett 406:276–280